


I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on November 14, 2008



Doran R. Pace, Patent Attorney

ELECTION UNDER 35 USC §121
Examining Group 1632
Patent Application
Docket No. USF.200TCXZ1
Serial No. 10/567,298

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Wu Cheng W. Shen, Ph.D.
Art Unit : 1632
Applicants : M. Ian Phillips, Yao Liang Tang
Serial No. : 10/567,298
Filed : February 6, 2006
Confirm. No. : 6761
For : Vigilant Cells

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ELECTION UNDER 35 USC §121

Sir:

In response to the written Restriction Requirement dated October 14, 2008 in the above-identified patent application, Applicants hereby elect to prosecute the invention of Group I (claims 1-20), without traverse. Applicants further elect heme oxygenase-1 (HO-1) as the single therapeutic product from claim 7, mesenchymal stem cell (MSC) as the single cell from claim 13, cardiac cell as the single cell from claim 14, and hypoxia as the single physiological stimulus from claim 19. Applicants note that the elected species for claims 14 and 19 have been added to the claims by the Preliminary Amendment that accompanies this Election.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Doran R. Pace
Patent Attorney
Registration No. 38,261
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

DRP/mv
Attachment: Preliminary Amendment